CHIKV RNA vaccines
AssigneeModernaTX, Inc.
InventorsGiuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
Life of this patent
Estimating the term…
Abstract
Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.
Claims24
A Chikungunya virus (CHIKV) vaccine, comprising:
- a ribonucleic acid (RNA) polynucleotide having an open reading frame encoding a CHIKV antigenic polypeptide comprising CHIKV E2 protein formulated in a lipid nanoparticle in an effective amount to produce an immune response in a subject administered the CHIKV vaccine, wherein the lipid nanoparticle comprises a cationic lipid, a PEG-modified lipid, a sterol, and a non-cationic lipid.
A Chikungunya virus (CHIKV) vaccine, comprising:
- a ribonucleic acid (RNA) polynucleotide having an open reading frame encoding a CHIKV antigenic polypeptide comprising CHIKV E2 protein formulated in a lipid nanoparticle in an effective amount to produce an immune response in a subject administered the CHIKV vaccine, wherein the lipid nanoparticle comprises a cationic lipid, a PEG-modified lipid, a sterol, and a non-cationic lipid, wherein the RNA polynucleotide is encoded by a nucleotide sequence selected from SEQ ID NO:
- 1-13.
A Chikungunya virus (CHIKV) vaccine, comprising a 5′ terminal cap, a ribonucleic acid (RNA) polynucleotide comprising an open reading frame encoding a CHIKV antigenic polypeptide comprising CHIKV E2 protein, and a polyA tail, wherein the RNA polynucleotide comprises a chemical modification and is formulated in a lipid nanoparticle in an effective amount to produce an immune response in a subject administered the CHIKV vaccine, wherein the lipid nanoparticle comprises a cationic lipid, a PEG-modified lipid, a sterol, and a non-cationic lipid.
A Chikungunya virus (CHIKV) vaccine, comprising a ribonucleic acid (RNA) polynucleotide having an open reading frame encoding a CHIKV antigenic peptide comprising a CHIKV E2 protein linked to a signal peptide formulated in a lipid nanoparticle in an effective amount to produce an immune response in a subject administered the CHIKV vaccine, wherein the lipid nanoparticle comprises a cationic lipid, a PEG-modified lipid, a sterol, and a non-cationic lipid.
Dependencies are inferred from the claim text.